Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.

Article  CAS  PubMed  Google Scholar 

Anan K, Mitsuyama S, Koga K, Tanabe R, Saimura M, Tanabe Y, et al. Disparities in the survival improvement of recurrent breast cancer. Breast Cancer. 2010;17(1):48–55.

Article  PubMed  Google Scholar 

Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100(1):44–52.

Article  PubMed  Google Scholar 

Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. Herceptin adjuvant trial study T, 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15(6):640–7.

Article  CAS  PubMed  Google Scholar 

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional based review. J Clin Oncol. 2010;28(1):92–8.

Article  CAS  PubMed  Google Scholar 

Witzel I, Müller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A, et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry. BMC Cancer. 2014;14:806.

Article  PubMed  PubMed Central  Google Scholar 

Masuda T, Fujimoto H, Teranaka R, Kuroda M, Aoyagi Y, Nagashima T, et al. Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer. Breast Cancer Res Treat. 2020;180(3):625–34.

Article  CAS  PubMed  Google Scholar 

Richard S, Selle F, Lotz JP, Khalil A, Gligorov J, Soares D. Pertuzumab and trastuzumab: the rationale way to synergy. An Acad Bras Cienc. 2016;88(1):565–77.

Article  CAS  PubMed  Google Scholar 

Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

Article  CAS  PubMed  Google Scholar 

Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer. 1999;79(5–6):707–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuroda M, Aoyagi Y, Asada S, Bujo H, Tanaka S, Konno S, et al. Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin: cholesterol acyltransferase deficiency. Open Gene Ther J. 2011;4:1–10.

Article  CAS  Google Scholar 

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on her2-positive human xenograft tumor models. Cancer Res. 2009. https://doi.org/10.1158/0008-5472.CAN-08-4597.

Article  PubMed  Google Scholar 

Kumar S, Markusic D, Biswas M, High K, Herzog R. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev. 2016;25(3):16034.

Article  Google Scholar 

Sun W, Shi Q, Zhang H, Yang K, Ke Y, Wang Y, et al. Advances in the techniques and methodologies of cancer gene therapy. Discover Med. 2019;27(146):45–55.

CAS  Google Scholar 

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park J, Rivière I, Gonen M, Wang X, Sénéchal B, Curran K, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wirth T, Ylä-Herttuala S. Gene therapy used in cancer treatment. Biomedicines. 2014;2(2):149–62.

Article  PubMed  PubMed Central  Google Scholar 

Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z, et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res. 2006;12(20 Pt 1):6179–85.

Article  CAS  PubMed  Google Scholar 

Kim H, Danishmalik S, Hwang H, Sin JI, Oh J, Cho Y, et al. Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2. Cancer Gene Ther. 2016;23(10):341–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanojia D, Balyasnikova I, Morshed R, Frank R, Yu D, Zhang L, et al. Neural stem cells secreting anti-HER2 antibody improve survival in a preclinical model of HER2 overexpressing breast cancer brain metastases. Stem Cells. 2015;33(10):2985–94.

Article  CAS  PubMed  Google Scholar 

Zafir-Lavie I, Sherbo S, Goltsman H, Badinter F, Yeini E, Ofek P, et al. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases. J Control Release. 2018;10(291):80–9.

Article  Google Scholar 

Spalding K, Arner E, Westermark P, Bernard S, Buchholz B, Bergmann O, et al. Dynamics of fat cell turnover in humans. Nature. 2008;453(7196):783–7.

Article  CAS  PubMed  Google Scholar 

Kronowitz S, Mandujano C, Liu J, Kuerer H, Smith B, Garvey P, et al. Lipofilling of the breast does not increase the risk of recurrence of breast cancer: a matched controlled study. Plast Reconstr Surg. 2016;137(2):385–93.

Article  CAS  PubMed  Google Scholar 

Wazir U, Chehade H, Headon H, Oteifa M, Kasem A, Mokbel K. Oncological safety of lipofilling in patients with breast cancer: a meta-analysis and update on clinical practice. Anticancer Res. 2016;36(9):4521–8.

Article  PubMed  Google Scholar 

Aoyagi Y, Kuroda M, Asada S, Tanaka S, Konno S, Tanio M, et al. Fibrin glue is a candidate scaffold for long-term therapeutic protein expression in spontaneously differentiated adipocytes in vitro. Exp Cell Res. 2012;318(1):8–15.

Article  CAS  PubMed  Google Scholar 

Rita Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343–6.

Article  PubMed  Google Scholar 

Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, et al. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer. 1996;73(11):1362–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo Y, Li W, Jiang Z, Zhang Q, Wang L, Mao Y, et al. Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Anticancer Drugs. 2019;30(8):866–72.

Article  CAS  PubMed  Google Scholar 

Ito M, Bujo H, Takahashi K, Arai T, Tanaka I, Saito Y. Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice. Diabetologia. 2005;48(8):1614–20.

Article  CAS  PubMed  Google Scholar 

Aso M, Yamamoto T, Kuroda M, Wada J, Kubota Y, Ishikawa K, et al. First-in-human autologous implantation of genetically modified adipocytes expressing LCAT for the treatment of familial LCAT deficiency. Heliyon. 2022. https://doi.org/10.1016/j.heliyon.2022.e11271.

Article  PubMed  PubMed Central  Google Scholar 

Muñoz M, Argüelles S, Guzman-Chozas M, Guillén-Sanz R, Franco J, Pintor-Toro J, et al. Cell tracking, survival, and differentiation capacity of adipose-derived stem cells after engraftment in rat tissue. J Cell Physiol. 2018;233(10):6317–28.

Article  PubMed  Google Scholar